Home » Topics » Regulatory » EMA

EMA
RSS

Lenalidomide approved in Australia and Canada, receives negative opinion in Europe

Jan. 29, 2008

EMEA issues opinion on safety of Gardasil

Jan. 29, 2008

EMEA recommends approval of novel oral anticoagulant, Pradaxa

Jan. 28, 2008

EMEA recommends suspension of marketing authorization of medicines containing aprotinin

Nov. 23, 2007

Novartis withdraws application to extend marketing authorization for Zometa

Nov. 22, 2007

MSD's Isentress for HIV-1 infection gets positive opinion from CHMP

Nov. 21, 2007

CHMP recommends Merck, Sharp and Dohme's Ivemend for nausea with chemotherapy

Nov. 21, 2007

Abbott voluntarily withdraws E.U. marketing authorization for Trudexa

Aug. 1, 2007

Bausch & Lomb Ireland withdraws Retisert marketing authorization application

July 27, 2007

Rasilez recommended for E.U. approval

June 25, 2007

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...